Ascertainment and verification of end-stage renal disease and end-stage liver disease in the north american AIDS cohort collaboration on research and design

Mari M. Kitahata, Daniel R. Drozd, Heidi M. Crane, Stephen E. Van Rompaey, Keri Althoff, Stephen J Gange, Marina B. Klein, Gregory M Lucas, Alison Gump Abraham, Vincent Lo Re, Justin McReynolds, William B. Lober, Adell Mendes, Sharada P Modur, Yuezhou Jing, Elizabeth J. Morton, Margaret A. Griffith, Aimee M. Freeman, Richard D Moore

Research output: Contribution to journalArticle

Abstract

The burden of HIV disease has shifted from traditional AIDS-defining illnesses to serious non-AIDS-defining comorbid conditions. Research aimed at improving HIV-related comorbid disease outcomes requires well-defined, verified clinical endpoints. We developed methods to ascertain and verify end-stage renal disease (ESRD) and end-stage liver disease (ESLD) and validated screening algorithms within the largest HIV cohort collaboration in North America (NA-ACCORD). Individuals who screened positive among all participants in twelve cohorts enrolled between January 1996 and December 2009 underwent medical record review to verify incident ESRD or ESLD using standardized protocols. We randomly sampled 6% of contributing cohorts to determine the sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of ESLD and ESRD screening algorithms in a validation subcohort. Among 43,433 patients screened for ESRD, 822 screened positive of which 620 met clinical criteria for ESRD. The algorithm had 100% sensitivity, 99% specificity, 82% PPV, and 100% NPV for ESRD. Among 41,463 patients screened for ESLD, 2,024 screened positive of which 645 met diagnostic criteria for ESLD. The algorithm had 100% sensitivity, 95% specificity, 27% PPV, and 100% NPV for ESLD. Our methods proved robust for ascertainment of ESRD and ESLD in persons infected with HIV.

Original languageEnglish (US)
Article number923194
JournalAIDS Research and Treatment
Volume2015
DOIs
StatePublished - 2015

Fingerprint

End Stage Liver Disease
Chronic Kidney Failure
Acquired Immunodeficiency Syndrome
Research Design
HIV
Sensitivity and Specificity
North America
Medical Records
Research

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Immunology and Allergy
  • Infectious Diseases
  • Dermatology

Cite this

Ascertainment and verification of end-stage renal disease and end-stage liver disease in the north american AIDS cohort collaboration on research and design. / Kitahata, Mari M.; Drozd, Daniel R.; Crane, Heidi M.; Van Rompaey, Stephen E.; Althoff, Keri; Gange, Stephen J; Klein, Marina B.; Lucas, Gregory M; Abraham, Alison Gump; Lo Re, Vincent; McReynolds, Justin; Lober, William B.; Mendes, Adell; Modur, Sharada P; Jing, Yuezhou; Morton, Elizabeth J.; Griffith, Margaret A.; Freeman, Aimee M.; Moore, Richard D.

In: AIDS Research and Treatment, Vol. 2015, 923194, 2015.

Research output: Contribution to journalArticle

Kitahata, Mari M. ; Drozd, Daniel R. ; Crane, Heidi M. ; Van Rompaey, Stephen E. ; Althoff, Keri ; Gange, Stephen J ; Klein, Marina B. ; Lucas, Gregory M ; Abraham, Alison Gump ; Lo Re, Vincent ; McReynolds, Justin ; Lober, William B. ; Mendes, Adell ; Modur, Sharada P ; Jing, Yuezhou ; Morton, Elizabeth J. ; Griffith, Margaret A. ; Freeman, Aimee M. ; Moore, Richard D. / Ascertainment and verification of end-stage renal disease and end-stage liver disease in the north american AIDS cohort collaboration on research and design. In: AIDS Research and Treatment. 2015 ; Vol. 2015.
@article{adf38be4d39c40b0b194e622c7c20ae9,
title = "Ascertainment and verification of end-stage renal disease and end-stage liver disease in the north american AIDS cohort collaboration on research and design",
abstract = "The burden of HIV disease has shifted from traditional AIDS-defining illnesses to serious non-AIDS-defining comorbid conditions. Research aimed at improving HIV-related comorbid disease outcomes requires well-defined, verified clinical endpoints. We developed methods to ascertain and verify end-stage renal disease (ESRD) and end-stage liver disease (ESLD) and validated screening algorithms within the largest HIV cohort collaboration in North America (NA-ACCORD). Individuals who screened positive among all participants in twelve cohorts enrolled between January 1996 and December 2009 underwent medical record review to verify incident ESRD or ESLD using standardized protocols. We randomly sampled 6{\%} of contributing cohorts to determine the sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of ESLD and ESRD screening algorithms in a validation subcohort. Among 43,433 patients screened for ESRD, 822 screened positive of which 620 met clinical criteria for ESRD. The algorithm had 100{\%} sensitivity, 99{\%} specificity, 82{\%} PPV, and 100{\%} NPV for ESRD. Among 41,463 patients screened for ESLD, 2,024 screened positive of which 645 met diagnostic criteria for ESLD. The algorithm had 100{\%} sensitivity, 95{\%} specificity, 27{\%} PPV, and 100{\%} NPV for ESLD. Our methods proved robust for ascertainment of ESRD and ESLD in persons infected with HIV.",
author = "Kitahata, {Mari M.} and Drozd, {Daniel R.} and Crane, {Heidi M.} and {Van Rompaey}, {Stephen E.} and Keri Althoff and Gange, {Stephen J} and Klein, {Marina B.} and Lucas, {Gregory M} and Abraham, {Alison Gump} and {Lo Re}, Vincent and Justin McReynolds and Lober, {William B.} and Adell Mendes and Modur, {Sharada P} and Yuezhou Jing and Morton, {Elizabeth J.} and Griffith, {Margaret A.} and Freeman, {Aimee M.} and Moore, {Richard D}",
year = "2015",
doi = "10.1155/2015/923194",
language = "English (US)",
volume = "2015",
journal = "AIDS Research and Treatment",
issn = "2090-1240",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Ascertainment and verification of end-stage renal disease and end-stage liver disease in the north american AIDS cohort collaboration on research and design

AU - Kitahata, Mari M.

AU - Drozd, Daniel R.

AU - Crane, Heidi M.

AU - Van Rompaey, Stephen E.

AU - Althoff, Keri

AU - Gange, Stephen J

AU - Klein, Marina B.

AU - Lucas, Gregory M

AU - Abraham, Alison Gump

AU - Lo Re, Vincent

AU - McReynolds, Justin

AU - Lober, William B.

AU - Mendes, Adell

AU - Modur, Sharada P

AU - Jing, Yuezhou

AU - Morton, Elizabeth J.

AU - Griffith, Margaret A.

AU - Freeman, Aimee M.

AU - Moore, Richard D

PY - 2015

Y1 - 2015

N2 - The burden of HIV disease has shifted from traditional AIDS-defining illnesses to serious non-AIDS-defining comorbid conditions. Research aimed at improving HIV-related comorbid disease outcomes requires well-defined, verified clinical endpoints. We developed methods to ascertain and verify end-stage renal disease (ESRD) and end-stage liver disease (ESLD) and validated screening algorithms within the largest HIV cohort collaboration in North America (NA-ACCORD). Individuals who screened positive among all participants in twelve cohorts enrolled between January 1996 and December 2009 underwent medical record review to verify incident ESRD or ESLD using standardized protocols. We randomly sampled 6% of contributing cohorts to determine the sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of ESLD and ESRD screening algorithms in a validation subcohort. Among 43,433 patients screened for ESRD, 822 screened positive of which 620 met clinical criteria for ESRD. The algorithm had 100% sensitivity, 99% specificity, 82% PPV, and 100% NPV for ESRD. Among 41,463 patients screened for ESLD, 2,024 screened positive of which 645 met diagnostic criteria for ESLD. The algorithm had 100% sensitivity, 95% specificity, 27% PPV, and 100% NPV for ESLD. Our methods proved robust for ascertainment of ESRD and ESLD in persons infected with HIV.

AB - The burden of HIV disease has shifted from traditional AIDS-defining illnesses to serious non-AIDS-defining comorbid conditions. Research aimed at improving HIV-related comorbid disease outcomes requires well-defined, verified clinical endpoints. We developed methods to ascertain and verify end-stage renal disease (ESRD) and end-stage liver disease (ESLD) and validated screening algorithms within the largest HIV cohort collaboration in North America (NA-ACCORD). Individuals who screened positive among all participants in twelve cohorts enrolled between January 1996 and December 2009 underwent medical record review to verify incident ESRD or ESLD using standardized protocols. We randomly sampled 6% of contributing cohorts to determine the sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of ESLD and ESRD screening algorithms in a validation subcohort. Among 43,433 patients screened for ESRD, 822 screened positive of which 620 met clinical criteria for ESRD. The algorithm had 100% sensitivity, 99% specificity, 82% PPV, and 100% NPV for ESRD. Among 41,463 patients screened for ESLD, 2,024 screened positive of which 645 met diagnostic criteria for ESLD. The algorithm had 100% sensitivity, 95% specificity, 27% PPV, and 100% NPV for ESLD. Our methods proved robust for ascertainment of ESRD and ESLD in persons infected with HIV.

UR - http://www.scopus.com/inward/record.url?scp=84924235741&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924235741&partnerID=8YFLogxK

U2 - 10.1155/2015/923194

DO - 10.1155/2015/923194

M3 - Article

C2 - 25789171

AN - SCOPUS:84924235741

VL - 2015

JO - AIDS Research and Treatment

JF - AIDS Research and Treatment

SN - 2090-1240

M1 - 923194

ER -